Antimicrobial Resistance in Curable Sexually Transmitted Infections

Curr HIV/AIDS Rep. 2025 Jan 25;22(1):14. doi: 10.1007/s11904-025-00722-7.

Abstract

Purpose of review: Antimicrobial resistance in sexually transmitted infections (STIs) has become an urgent global public health threat, raising the specter of untreatable infections. This review summarizes the determinants of resistance among the five most common curable STIs Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Treponema pallidum, and Trichomonas vaginalis, as well as strategies to mitigate the spread of resistance.

Recent findings: Genetic mutations are key drivers of resistance for N. gonorrhoeae and M. genitalium. Resistance in T. vaginalis can also occur because of genetic mutations, yet differential regulation of genes critical in antibiotic metabolism as well as co-infection with organisms that inactivate therapy play important roles. While resistance in C. trachomatis and T. pallidum has not been a substantial clinical concern, resistance selection via the continued widespread use of antimicrobials remains possible. While resistance determinants are diverse and differ by pathogen, the strategies required to mitigate the continued emergence of resistance are similar: prevention of infection and treatment diversification. Underpinning those strategies, surveillance remains essential for monitoring and responding to the threat of drug-resistant infections.

Keywords: Chlamydia trachomatis; Mycoplasma genitalium; Neisseria gonorrhoeae; Treponema pallidum; Trichomonas vaginalis; Antimicrobial resistance; Sexually transmitted infections.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Chlamydia trachomatis / drug effects
  • Drug Resistance, Bacterial*
  • Gonorrhea / drug therapy
  • Humans
  • Mycoplasma genitalium / drug effects
  • Mycoplasma genitalium / genetics
  • Neisseria gonorrhoeae / drug effects
  • Neisseria gonorrhoeae / genetics
  • Sexually Transmitted Diseases* / drug therapy
  • Sexually Transmitted Diseases* / microbiology
  • Treponema pallidum / drug effects
  • Trichomonas vaginalis / drug effects
  • Trichomonas vaginalis / genetics

Substances

  • Anti-Bacterial Agents